Christopher S King

20070244128, Oct 18, 2007

May 7, 2007

11/745387

John HUTCHINSON - La Jolla CA, US
Christopher King - Carlsbad CA, US
Thomas Seiders - San Diego CA, US

AMIRA PHARMACEUTICALS, INC. - San Diego CA

A61K 31/40
A61K 31/44
A61K 31/47
A61K 31/4965
A61P 11/06

514255050, 514314000, 514339000, 514412000, 544405000, 546152000, 546277400, 548452000

Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.

20090291981, Nov 26, 2009

May 22, 2009

12/471106

Kevin Murray SCHAAB - Spring Valley CA, US
Christopher David KING - Carlsbad CA, US
Nicholas Simon STOCK - San Diego CA, US

AMIRA PHARMACEUTICALS, INC. - San Diego CA

A61K 31/444
C07D 401/14
A61P 11/06

514333, 546256

Described herein is the FLAP inhibitor 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxy-pyridin-3-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the FLAP inhibitor, or a pharmaceutically acceptable salt thereof, including solvates, and polymorphs thereof. Also described herein are pharmaceutical compositions suitable for administration to a mammal that include the FLAP inhibitor, or a pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating respiratory conditions or diseases, as well as other leukotriene-dependent or leukotriene mediated conditions or diseases.

20100075934, Mar 25, 2010

Oct 24, 2008

12/257876

Melissa Virginia REWOLINSKI - San Diego CA, US
Kevin Murray SCHAAB - Spring Valley CA, US
Christopher David KING - Carlsbad CA, US
Jillian F. EVANS - San Diego CA, US
Petpiboon Peppi PRASIT - Rancho Santa Fe CA, US
John Howard HUTCHINSON - La Jolla CA, US
Nicholas Simon STOCK - San Diego CA, US

Amira Pharmaceuticals, Inc. - San Diego CA

A61K 31/444
A61K 31/56
C07D 401/14
A61P 11/00

514171, 514333, 546256

Described herein are methods for the synthesis of 3-[5-(pyridin-2-ylmethoxy)-3-(2-methyl-2-propylthio)-1-[4-(2-methoxypyridin-5-yl)benzyl]-indol-2-yl]-2,2-dimethyl-propionic acid, pharmaceutically acceptable salts, pharmaceutically acceptable solvates thereof. Also described are pharmaceutical compositions suitable for oral administration to a mammal that include, as well as methods of using such oral pharmaceutical compositions for treating respiratory conditions or diseases, as well as other leukotriene-dependent or leukotriene mediated conditions or diseases.

20110034558, Feb 10, 2011

Jul 29, 2010

12/846690

Jason Edward BRITTAIN - El Cajon CA, US
Brian Andrew STEARNS - Encinitas CA, US
Christopher David KING - Carlsbad CA, US
Kevin Ross HOLME - San Diego CA, US

AMIRA PHARMACEUTICALS, INC. - San Diego CA

A61K 31/195
C07C 59/135
A61P 29/00
A61P 37/08
A61P 27/02
A61P 17/00
A61P 11/00

514564, 562439

Described herein is the DPantagonist [2′-(3-benzyl-1-ethyl-ureidomethyl)-6-methoxy-4′-trifluoromethyl-biphenyl-3-yl]-acetic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the DP2 antagonist, or a pharmaceutically acceptable salt thereof. Also described herein are pharmaceutical compositions suitable for administration to a mammal that include the DPantagonist, or a pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating respiratory diseases or conditions, allergic diseases or conditions, inflammatory diseases or conditions, as well as other prostaglandin D-dependent or prostaglandin D-mediated diseases or conditions.

20130053444, Feb 28, 2013

Jan 5, 2011

13/519292

Jason Edward Brittain - El Cajon CA, US
Christopher David King - Carlsbad CA, US
Brian Andrew Stearns - Encinitas CA, US

PANMIRA PHARMACEUTICALS, LLC - San Diego CA

A61K 31/196
A61P 11/00
A61P 29/00
A61P 11/02
A61P 11/06
A61P 37/00
A61P 27/02
A61P 17/00
C07C 321/10
A61P 37/08

514562, 562426

Described herein is the DPanatgonist 2-(3-(2-((tert-butylthio)methyl)-4-(2,2-dimethyl-propionylamino)phenoxy)-4-methoxyphenyl)acetic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the DPanatgonist, or a pharmaceutically acceptable salt thereof. Also described herein are pharmaceutical compositions suitable for administration to a mammal that include the DPanatgonist, or a pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating respiratory diseases or conditions, allergic diseases or conditions, inflammatory diseases or conditions, as well as other prostaglandin D-dependent or prostaglandin D-mediated diseases or conditions.

20130253023, Sep 26, 2013

Dec 7, 2011

13/992022

Jason Edward Brittain - El Cajon CA, US
Thomas Jon Seiders - San Diego CA, US
Christopher David King - Carlsbad CA, US
Victor W. Rosso - East Windsor NJ, US

C07D 261/14

514380, 5483725

Described herein is the LPA1 antagonist 1-{4′-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-bi-phenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1), or pharmaceutically acceptable salts thereof. Also described are methods of preparing the LPA1 antagonist, or pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions suitable for administration to a mammal that include the LPA1 antagonist, or pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating LPA-dependent or LPA-mediated diseases or conditions.

20170121295, May 4, 2017

Dec 16, 2016

15/381562

- Princeton NJ, US
Christopher David KING - Carlsbad CA, US
Victor W. ROSSO - East Windsor NJ, US

AMIRA PHARMACEUTICALS, INC. - Princeton NJ
BRISTOL-MYERS SQUIBB COMPANY - Princeton NJ

C07D 261/14

Described herein is the LPA1 antagonist 1-{4′-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1), or pharmaceutically acceptable salts thereof. Also described are methods of preparing the LPA1 antagonist, or pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions suitable for administration to a mammal that include the LPA1 antagonist, or pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating LPA-dependent or LPA-mediated diseases or conditions.

20160136119, May 19, 2016

Aug 25, 2014

14/468183

- Miami FL, US
Brian Andrew Stearns - Encinitas CA, US
Christopher David King - Carlsbad CA, US
Kevin Ross Holme - San Diego CA, US

A61K 31/195

Described herein is the DPantagonist [2′-(3-benzyl-1-ethyl-ureidomethyl)-6-methoxy-4′-trifluoromethyl-biphenyl-3-yl]-acetic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the DP2 antagonist, or a pharmaceutically acceptable salt thereof. Also described herein are pharmaceutical compositions suitable for administration to a mammal that include the DPantagonist, or a pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating respiratory diseases or conditions, allergic diseases or conditions, inflammatory diseases or conditions, as well as other prostaglandin D-dependent or prostaglandin D-mediated diseases or conditions.